老虎证券

BRIEF-Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity

Reuters
04-07
BRIEF-Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity

April 7 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:

  • RHYTHM PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE 3 TRANSCEND TRIAL MEETS PRIMARY ENDPOINT WITH -19.8% PLACEBO-ADJUSTED BMI REDUCTION IN PATIENTS (N=120) WITH ACQUIRED HYPOTHALAMIC OBESITY

  • RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE THERAPY ACHIEVES -16.5% MEAN BMI CHANGE IN PATIENTS

  • RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE ACHIEVES -19.2% PLACEBO-ADJUSTED BMI REDUCTION IN ADULTS

  • RHYTHM PHARMACEUTICALS INC - REGULATORY SUBMISSIONS IN U.S. AND EU EXPECTED Q3 2025

  • RHYTHM PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED WITH -16.5% MEAN BMI REDUCTION

  • RHYTHM PHARMACEUTICALS INC - NO NEW SAFETY SIGNALS OBSERVED WITH SETMELANOTIDE

Source text: ID:nGNX6NQcwV

Further company coverage: RYTM.O

(((( Reuters.briefs@thomsonreuters.com ;));))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10